Citius Oncology (CTOR) Retained Earnings (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Retained Earnings data on file, last reported at -$96.2 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 79.2% year-over-year to -$96.2 million in Q1 2026; TTM through Mar 2026 was -$96.2 million, a 79.2% decrease from a year earlier, with the FY2025 full-year figure at -$64.0 million, down 174.98% from the prior year.
• Retained Earnings for Q1 2026 stood at -$96.2 million, down from -$69.6 million in the prior quarter.
• Over the last five years, Retained Earnings for CTOR reached as high as $85.4 million in Q3 2024 and fell as low as -$96.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$19.0 million across 5 years, with a median of -$2.7 million in 2024.
• On a YoY basis, Retained Earnings climbed as much as 95.63% in 2024 and fell as far as 137461.86% in 2024.
• Year by year, Retained Earnings stood at $345266.0 in 2022, then plunged by 675.71% to -$2.0 million in 2023, then tumbled by 2211.07% to -$45.9 million in 2024, then sank by 51.45% to -$69.6 million in 2025, then plunged by 38.25% to -$96.2 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$96.2 million in Q1 2026, -$69.6 million in Q4 2025, and -$64.0 million in Q3 2025.